Clinical trial
A Phase 2b Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
NCT02878330 is registered in ClinicalTrials.gov with MedImmune LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2b Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of MEDI8897, a Monoclonal Antibody With an Extended Half-life Against Respiratory Syncytial Virus, in Healthy Preterm Infants
- Lead sponsor
- MedImmune LLC
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- November 3, 2016
- Completion date
- December 6, 2018
- Enrollment
- 1,453 (actual)
- Sites
- 161
Conditions
As the registry lists them; a condition with its own page is linked.